Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study

Autor: Kaplanov, K. D., ÖZCAN, MEHMET ALİ, Udovitsa, D. P., Ilyin, N., Alekseev, S. M., Fadjari, H., Arumugan, V., Chakrabarti, P., Kirushnakumar, K. S., Attili, A. V. S. Suresh, Dantas da Cunha Junior, A., Schmidt Filho, J., Franke, F. A., Sampaio Tavares, R., Pinto Simoes, B., Miguel, C. E., Meton, F., Boquimpani, C., Schaffel, R., Cigno, E. L., Basso, A. C., Jarchum, G., Heller, V. B., Bullorsky, E., Furque, M. L., Jones, L., Bassa, F., Osmanov, D. S., Burdaeva, O. N., Melnichenko, V. Y., Uy, N. A., Keat, C. Teng, Rosales, J. D., Galvez, K., Lazaretti, N., Debiasi, M., Santi, P. Xavier, de Mattos, E. R., Luiz da Silva, R., Rodrigues de Oliveira, J. S., Pereira, J., Salvino de Araujo, A., Fogliatto, L., Beguelin, G. Z., Saslavsky, M. M., Munoz, M., Avila, G. I., Moiseevich, M. G., Viktorovich, P. A., Tiangco, B. J., Molina Barrios, G. R., Martinez-Lapus, F. G. P., Villegas, E. M., Raman, R., Gin, G. Gin, Bermudez, C., Ciliao Munhoz, E., Garcia, J. J., De Stefano, G., Caffaro, J., Syafei, S., da Silva Araujo, S. Shusterschitz, Kowalyszyn, R. D., Jasuja, S., Bhurani, D., Radhakrishnan, V., Salvatierra, A., Mukhopadhyay, A., Bhattacharyya, S., Bhatt, N., Perez Diaz, Luis, Paravisini, Alexandra, Fogliatto, Laura, Nodehi, Sayyed Reza Safaee, Patel, Moosa, Volodicheva, Elena Mikhailovna, Lipatov, Oleg Nikolaevich, Guan, Toh See, Querol, John, Flores, David Hugo, Dasappa, Lokanatha, Beniwal, Surender Kumar, Bar, Daniel Oscar, Delamain, Marcia Torresan, Gonzalez, Derlis E., Candelaria, Myrna, Florez, A., Michiels, S., Leao, D., Loggetto, S. R., Szpak, W., Lifirenko, I. D., Ponomarev, R. S., Lysenko, I. B., Vladimirov, V.

Publikováno v: Leukemialymphoma. 60(14)

This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914865134a0fa1b9718405e5d0316a01
https://pubmed.ncbi.nlm.nih.gov/31432721

TREATMENT OUTCOMES IN CLASSICAL HODGKIN LYMPHOMA (HL): 5-YEAR UPDATE REPORT FROM THE BRAZILIAN PROSPECTIVE REGISTRY

Autor: Biasoli, I, Castro, N, Villarim, CC, Traina, F, Chiattone, CS, Praxedes, M, Solza, C, Perobelli, L, Baiocchi, O, Gaiolla, R, Boquimpani, C, Buccheri, V, Sola, CB, Silva, ROPE, Ribas, AC, Steffenello, G, Pagnano, K, Soares, A, Medina, SS, Silveira, T, Cecyn, KZ, Goveia, L, Palma, LC, Marques, MO, Souza, C, Spector, N

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2022 44 Supplement 2:S81-S82

MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors

Autor: Atallah, EL, Maheshwari, V, Mauro, MJ, Boquimpani, C, Réa, D, Hochhaus, A, Minami, Y, Saini, L, Corbin, R

Publikováno v: In Value in Health July 2022 25(7) Supplement:S521-S521

COVID-19 IN CHRONIC MYELOID LEUKEMIA PATIENTS – BRAZILIAN EXPERIENCE

Autor: Pagnano, KBB, Toreli, AC, Quixadá, AT, Perobelli, L, Funke, VAM, Seguro, FS, Bendit, I, Fechio, LVDN, Sapelli, J, Bortolini, J, Moura, MS, Lourenço, AG, Gonçalves, NN, Conchon, M, Nucci, F, Palma, LC, Hokama, POM, Almeida, LL, Souza, CA, Boquimpani, C

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2021 43 Supplement 1:S531-S532